Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination
Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved..
OBJECTIVES: COVID-19 vaccine breakthrough infections were frequently reported during circulation of the Omicron variant. The ANRS|MIE CoviCompareP study investigated these infections in adults vaccinated and boosted with BNT162b2 [Pfizer-BioNTech] and with/without SARS-CoV-2 infection before vaccination.
METHODS: In the first half of 2021, healthy adults (aged 18-45, 65-74 and 75 or older) received either one dose of BNT162b2 (n = 120) if they had a documented history of SARS-CoV-2 infection at least five months previously, or two doses (n = 147) if they had no history confirmed by negative serological tests. A first booster dose was administered at least 6 months after the primary vaccination, and a second booster dose, if any, was reported in the database. Neutralizing antibodies (NAbs) against the European (D614G) strain and the Omicron BA.1 variant were assessed up to 28 days after the first booster dose. A case-control analysis was performed for the 252 participants who were followed up in 2022, during the Omicron waves.
RESULTS: From January to October 2022, 78/252 (31%) had a documented symptomatic breakthrough infection after full vaccination: 21/117 (18%) in those who had been infected before vaccination vs. 57/135 (42%) in those who had not. In a multivariate logistic regression model, factors associated with a lower risk of breakthrough infection were older age, a higher number of booster doses, and higher levels of Omicron BA.1 NAb titers in adults with infection before vaccination, but not in those without prior infection.
CONCLUSION: Our results highlight the need to consider immune markers of protection in association with infection and vaccination history.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Infectious diseases now - 54(2024), 5 vom: 16. März, Seite 104886 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Durier, Christine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breakthrough infections |
|---|
| Anmerkungen: |
Date Revised 26.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.idnow.2024.104886 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369838076 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369838076 | ||
| 003 | DE-627 | ||
| 005 | 20240328000220.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.idnow.2024.104886 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM369838076 | ||
| 035 | |a (NLM)38494117 | ||
| 035 | |a (PII)S2666-9919(24)00041-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Durier, Christine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a OBJECTIVES: COVID-19 vaccine breakthrough infections were frequently reported during circulation of the Omicron variant. The ANRS|MIE CoviCompareP study investigated these infections in adults vaccinated and boosted with BNT162b2 [Pfizer-BioNTech] and with/without SARS-CoV-2 infection before vaccination | ||
| 520 | |a METHODS: In the first half of 2021, healthy adults (aged 18-45, 65-74 and 75 or older) received either one dose of BNT162b2 (n = 120) if they had a documented history of SARS-CoV-2 infection at least five months previously, or two doses (n = 147) if they had no history confirmed by negative serological tests. A first booster dose was administered at least 6 months after the primary vaccination, and a second booster dose, if any, was reported in the database. Neutralizing antibodies (NAbs) against the European (D614G) strain and the Omicron BA.1 variant were assessed up to 28 days after the first booster dose. A case-control analysis was performed for the 252 participants who were followed up in 2022, during the Omicron waves | ||
| 520 | |a RESULTS: From January to October 2022, 78/252 (31%) had a documented symptomatic breakthrough infection after full vaccination: 21/117 (18%) in those who had been infected before vaccination vs. 57/135 (42%) in those who had not. In a multivariate logistic regression model, factors associated with a lower risk of breakthrough infection were older age, a higher number of booster doses, and higher levels of Omicron BA.1 NAb titers in adults with infection before vaccination, but not in those without prior infection | ||
| 520 | |a CONCLUSION: Our results highlight the need to consider immune markers of protection in association with infection and vaccination history | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breakthrough infections | |
| 650 | 4 | |a COVID-19 mRNA vaccine | |
| 650 | 4 | |a Neutralization antibodies | |
| 650 | 4 | |a Omicron | |
| 700 | 1 | |a Ninove, Laetitia |e verfasserin |4 aut | |
| 700 | 1 | |a van der Werf, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Lefebvre, Maeva |e verfasserin |4 aut | |
| 700 | 1 | |a Desaint, Corinne |e verfasserin |4 aut | |
| 700 | 1 | |a Bauer, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Attia, Mikael |e verfasserin |4 aut | |
| 700 | 1 | |a Lecompte, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Lachatre, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Maakaroun-Vermesse, Zoha |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolas, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Verdon, Renaud |e verfasserin |4 aut | |
| 700 | 1 | |a Kiladjian, Jean-Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Loubet, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt-Mutter, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Corbin, Violaine |e verfasserin |4 aut | |
| 700 | 1 | |a Ansart, Séverine |e verfasserin |4 aut | |
| 700 | 1 | |a Melica, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Resch, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Netzer, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Kherabi, Yousra |e verfasserin |4 aut | |
| 700 | 1 | |a Tardieu, Raphaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Lelièvre, Jean-Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Tartour, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a de Lamballerie, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Launay, Odile |e verfasserin |4 aut | |
| 700 | 0 | |a ANRS002S CoviCompareP group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases now |d 2021 |g 54(2024), 5 vom: 16. März, Seite 104886 |w (DE-627)NLM309051266 |x 2666-9919 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2024 |g number:5 |g day:16 |g month:03 |g pages:104886 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.idnow.2024.104886 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2024 |e 5 |b 16 |c 03 |h 104886 | ||